US5399346A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Gene therapy
Assignee: HEALTH AND HUMAN SERVICES DEPARTMENT OF United States, AS REPRESENTED BY SECRETARY
•
Filing: 1994-03-30
•
Granted: 1995-03-21
•
Expires: 2014-03-30
Abstract
Abstract Primary human cells which are genetically engineered with DNA (RNA) encoding a marker or therapeutic which is expressed to be expressed in vivo. Such engineered cells may be used in gene therapy.
Inventors
- 👤 W. French Anderson
- 👤 R. Michael Blaese
- 👤 Steven A. Rosenberg
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:14
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/525; A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/20; A61K40/00; A61K40/10; A61K40/11; A61K40/40; A61K40/41; A61K40/42; A61K40/4231; A61K40/4232; A61K2239/00; A61K2239/31; A61K2239/38; A61K48/00
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
52 words
A process for providing a human with a therapeutic protein comprising: introducing human cells into a human, said human cells having been treated in vitro to insert therein a DNA segment encoding a therapeutic protein said human cells expressing in vivo in said human a therapeutically effective amount of said therapeutic protein.
Claim 2
Dependent Claim
52 words
A process for providing a human with a therapeutic protein comprising: introducing human cells into a human, said human cells having been treated in vitro to insert therein a DNA segment encoding a therapeutic protein said human cells expressing in vivo in said human a therapeutically effective amount of said therapeutic protein.
Claim 3
Dependent Claim
11 words
The process of claim 1 wherein said cells are blood cells.
Claim 4
Dependent Claim
10 words
The process of claim 1 wherein said cells are leukocytes.
Claim 5
Dependent Claim
10 words
The process of claim 1 wherein said cells are lymphocytes.
Claim 6
Dependent Claim
10 words
The process of claim 1 wherein said cells are T-lymphocytes.
Claim 7
Dependent Claim
11 words
The process of claim 1 wherein said cells are TIL cells.
Claim 8
Dependent Claim
10 words
The process of claim 1 wherein said cells are B-lymphocytes.
Claim 9
Dependent Claim
24 words
The process of any one of claims 1-7 wherein said DNA segment has been inserted into said cells in vitro by a viral vector.
Claim 10
Dependent Claim
13 words
The process of claim 8 wherein said viral vector is a retroviral vector.
Claim 11
Dependent Claim
15 words
The process of any one of claims 1-7 wherein the DNA segment encodes a cytokine.
Claim 12
Dependent Claim
10 words
The process of claim 10 wherein the cytokine is TNF.
Claim 13
Dependent Claim
11 words
The process of claim 10 wherein the cytokine is an interleukin.
Claim 14
Dependent Claim
21 words
The process of claim 10 wherein said DNA segment has been inserted into said cells in vitro by a viral vector.
Claim 15
Dependent Claim
13 words
The process of claim 13 wherein said viral vector is a retroviral vector.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-03-20 | 1998-09-19 | 1999-03-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-03-20 | 2002-09-19 | 2003-03-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-03-20 | 2006-09-19 | 2007-03-21 | $7700.00 | Window Closed / Lapsed |